PDL BioPharma Inc

PDL BioPharma — Q2 2019 Earnings Presentation

16 slides from PDL BioPharma's earnings presentation, Aug 7, 2019

  1. Slide 1: 2019 Second Quarter Financial Results Conference Call

    PDL 2019 Second Quarter Financial Results Conference Call August 7, 2019

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements including PDL's expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual

  3. Slide 3: Second Quarter 2019 Overview

    Second Quarter 2019 Overview o Strategic shift to build focused portfolio of actively managed operating companies o Completion of Evofem Biosciences securities transaction = Total $60 million investment = Collaborating with Evofem team to support launch of Amphora® = Q2 non-cash gain on investment o

  4. Slide 4: Evofem Exemplifies PDL Growth Strategy

    Evofem Exemplifies PDL Growth Strategy o Strong fit with PDL’s mission to create value for shareholders and patients = Enables Evofem to maximize potential of novel therapeutics to address underserved needs « Significant revenue potential for Amphora through sizable market opportunity o CEO Dominiqu

  5. Slide 5: Evofem: Terms of Transaction

    Evofem: Terms of Transaction Oo Oo Oo Oo Total investment of $80 million; $60 million by PDL 2 PDL tranches of $30 million each closed on April 11% and June = Investment price of $4.50 per share 10th = Long-time EVFM investors, Woodford Investment Management and Invesco Asset Management, invested $1

  6. Slide 6: Factors Supporting Evofem Investment

    Factors Supporting Evofem Investment o Amphora®: investigational, on-demand, acid-buffering MVP-R™ vaginal gel with bio-adhesive properties o Results of AMPOWER Phase 3 study = Met primary endpoint of prevention of pregnancy = Favorable safety profile and well tolerated = Analysis of an exploratory

  7. Slide 7: Evofem: Multiple Near-Term Catalysts

    Evofem: Multiple Near-Term Catalysts o Re-submit NDA: Amphora® for prevention of 4Q-2019 pregnancy o Top-line Phase 2b data: Amphora® for prevention 4Q-2019 of chlamydia o PDUFA date: Amphora® for prevention of 2Q-2020* pregnancy o Commercial Launch: Amphora® for prevention of 2H-2020 pregnancy** *

  8. Slide 8: PDL: Well Positioned to Execute Strategy

    PDL: Well Positioned to Execute Strategy o Liquid balance sheet with $285 million in cash; $521 million expected in royalty rights through 2026 o Experienced team in sourcing, executing and consummating transactions, and positioning businesses for profitable growth o Continuing to evaluate opportuni

  9. Slide 9: Share Repurchase Program Update

    Share Repurchase Program Update o Completed the $100 million stock repurchase program in July (was authorized by board in September 2018) » Repurchased 31.0 million shares at an average price of $3.22 per share o Completed three share repurchase programs since 2017 » Used $155 million to repurchase

  10. Slide 10: LENSAR: Robust Growth and Continued Innovation

    LENSAR: Robust Growth and Continued Innovation o Revenues of $7.4 million in Q2 2019 = 26% increase over Q2 2018; 10% increase over Q1 2019 o Significant growth potential in the refractive cataract surgery market » #1 surgical procedure globally by volume o Clear innovation leader in cataract surger

  11. Slide 11: Noden: Continued Focus on Profitability

    "1 Noden: Continued Focus on Profitability o Actions to increase the profitability of Tekturna® in the U.S. and mitigate the impact of generic competition include: = Launched authorized generic (AG) version of Tekturna (aliskiren) in March 2019 through Prasco Laboratories — Branded Tekturna and auth

  12. Slide 12: Second Quarter 2019 Financials (unaudited)

    Second Quarter 2019 Financials (unaudited) Three Months Ended Six Months Ended June 30, June 30, (In thousands, except per share amounts) 2019 2018 2019 2018 Product revenue, net $ 17837 § 31761 _§ 44523 _§ 55,085 Royatty rights - change in fair value (40.399) 12.842 (28.142) 23.933 Royaties from Qu

  13. Slide 13: Second Quarter 2019 Financials (unaudited)

    13 Second Quarter 2019 Financials (unaudited) GAAP to Non-GAAP Net (Loss) Income Reconciliation (in thousands) ‘Three Months Ended ‘Six Months Ended ‘June 30, June 30, 2019 2018 2019 2018 ‘GAP net Joss) income attbuted to PDL's shareholders, as reported $4419) _s 12296) $2261 _$.(110,694) Adjustment

  14. Slide 14: Second Quarter 2019 Financials (unaudited)

    Second Quarter 2019 Financials (unaudited) ae, balance sheet data June 30, December 31, 2019 2018 Cash and cash equivalents $ 284,941 $ 394,590 Notes receivable $ 63,827 $ 63,813 Royalty rights - at fair value $ 315,642 $ 376,510 Investment in equity affiliate $ 88,533 $ s Intangible assets, net $ 5

  15. Slide 15: 2019 Guidance

    2019 Guidance Oo Oo Oo Noden product revenue of $50-55 million LENSAR product revenue of $27-29 million Cash royalties guidance raised to $60-65 million Evofem = Mark-to-market adjustments based on stock price at quarter close = Booked as non-operating income or loss as change in fair value to equit

  16. Slide 16: Questions & Answers

    PDL Questions & Answers

PDL BioPharma — Q2 2019 Earnings Presentation on 6ix